Recent findings of the Central Drugs Standard Control Organization (CDSCO) indicate that 48 medications out of 1,273 are of "substandard quality" and one drug is "spurious." The drug regulator conducted the assessment in June of this year.
According to the drug alert list issued last week, Rantidine Tablets, Rosuvastatin and Vitamin D3 Tablets, Erythromycin Stearate Tablets IP, Paracetamol Tablets, Telmisartan, and Albendazole are some of the drugs that were flagged in the drug alert list. The drug that was declared spurious is Heparin injection which is used to treat blood clots.
In the meantime, 12 of the 48 medications have connections to Himachal Pradesh's pharmaceutical companies. Asthma sufferers' Flutrol 250 inhalation was also discovered to be deficient in the necessary test content, according to the drug authority.
Some of the medications mentioned are used to prevent and treat dangerous blood clots, asthma, blood pressure, swelling brought on by heart disease, coughing, and peptic ulcers. Additionally, the drug regulator has also raised concerns about two dietary supplements, one of which is supposed to stop hair loss and the other aids in the production of red blood cells.
According to the list, most of the flagged drugs either failed the dissolution test or lacked the requisite assay content.
Maxheal Pharmaceuticals, Zee Laboratories, Hindustan Antibiotics Ltd., Cadila Pharmaceuticals, Alkem Health Science (A unit of Alkem Laboratories Limited) are some of the manufacturers whose drugs were flagged by the drug regulator.